Plasma-SeqSensei™ (PSS) assays enable highly sensitive and quantitative detection of mutations in circulating tumour DNA (ctDNA) from the blood plasma of cancer patients by utilising next-generation sequencing technology. PSS's short and standardised workflow delivers results within two days including the generation of easy-to-read reports using laptop-compatible Plasma-SeqSensei™ IVD Software. PSS Solid Cancer IVD Kit is intended to support clinicians with detecting minimal residual disease; recurrence surveillance; (neo-)adjuvant response monitoring; and analysing the RAS mutation status to determine the potential benefit of anti-epidermal growth factor receptor (EGFR) therapy for colorectal cancer patients.
Solid Tumor
BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), KRAS (KRAS proto-oncogene GTPase), NRAS (Neuroblastoma RAS viral oncogene homolog), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
Next-Generation Sequencing (NGS) / Circulating tumor DNA (ctDNA)